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Introduction
The incidence of arrhythmias may increase during preg-
nancy owing to the hyperdynamic state. Most healthy
pregnant women with transient arrhythmias have a
good prognosis and do not require antiarrhythmic
treatment. However, arrhythmias linked with underlying
heart disease, particularly congenital heart disease, can
result in serious hemodynamic deterioration. All anti-
arrhythmic agents can potentially cause adverse effects
in both mother and fetus during pregnancy. As med-
ical and surgical treatment for heart disease improves,
obstetricians may encounter more pregnant women
with congenital or rheumatic heart disease, so being
both alert to and familiar with the issues relating to
pregnant women with arrhythmias is important.
Here, we present a case of a woman whose preg-
nancy was complicated by atrial fibrillation (AF) with
rapid ventricular response (RVR) and hemodynamic
instability, who was successfully treated with electrical
cardioversion and sotalol.
Case Report
A 35-year-old woman, gravida 3, para 1, abortus 1, with
a 5-year history of arrhythmia without need for med-
ication, presented at 22 weeks’ gestation. During this
pregnancy, she had experienced frequent palpitation
attacks that were spontaneously relieved by rest. This
was followed by persistent palpitations and chest dis-
comfort. She went to the emergency room of the West
Garden Hospital, where a complete electrocardiogram
(EKG) showed supraventricular arrhythmia (SVT), with
a ventricular rate of 185 beats per minute (bpm). Labo-
ratory data including complete blood count, renal func-
tion, liver function, electrolytes and cardiac enzymes were
all within normal limits. The patient failed to respond
to the rapid administration of three intravenous doses
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of 12 mg of adenosine. Verapamil 2.5 mg was later given
twice, but also without success. She was then transferred
to our emergency room. A complete EKG showed SVT
with a heart rate (HR) of 180 bpm. Adenosine 12 mg
rapid intravenous push was prescribed, after which her
HR fell from 186 bpm to 138 bpm, and her EKG showed
AF with RVR. Unfortunately, the patient’s HR quickly
rose again to 182 bpm. Two doses of intravenous vera-
pamil 2.5 mg were prescribed, but with short-term re-
sponses. Amiodarone was avoided on account of its
potential adverse effect on fetal thyroid function. Because
of persistent arrhythmia (SVT, AF with RVR) refractory
to medication, external electrical cardioversion was in-
dicated. A synchronized direct current (DC) shock
(100 J) was performed under sedation. Following car-
dioversion, the maternal HR returned to sinus rhythm
and the fetal heartbeats were stable. However, SVT
with HR 180–190 bpm and blood pressure (BP) 91/
60 mmHg recurred again 2 hours later. A second electri-
cal cardioversion (synchronized 100 J) was performed.
The maternal HR returned to sinus rhythm without fetal
heartbeat deceleration. Two-dimensional echocardio-
graphy revealed moderate mitral regurgitation, mod-
erate to severe tricuspid regurgitation, dilated right and
left atria and normal left ventricular size with good left
ventricular contractility. A third SVT attack occurred
again 2 hours later but again returned to sinus rhythm
after a third electrical cardioversion (synchronized 50 J).
Sotalol 80 mg twice daily was prescribed, and the patient
was admitted to the intensive cardiac care unit for fur-
ther observation. One further episode of SVT occurred in
the intensive cardiac care unit and was returned to nor-
mal sinus rhythm (80–90 bpm) after a fourth DC shock
(synchronized 50 J) under propofol (class B) sedation.
After this, the patient’s condition remained stable.
Follow-up laboratory data showed anemia (hemo-
globin fell from 11.8 g/dL to 7.7 g/dL), electrolyte im-
balance, and hypoalbuminemia. No evidence of internal
bleeding or hemolysis was noted. Packed red blood cells
1,000 mL were transfused to correct the anemia and to
reduce the cardiac load. Thyroid function tests and anti-
nuclear antibodies were all within normal limits. There
were no further episodes of arrhythmia, and the patient
was discharged in a stable condition 6 days later. Oral
sotalol 80mg twice daily was maintained after discharge.
EKG follow-up 1 week later in the outpatient
department showed normal sinus rhythm with a rate of
63 bpm. The patient’s BP was 120/60 mmHg. Unfortu-
nately, however, at 26 weeks’ gestation, palpitations
returned while sleeping and persisted for more than 
2 hours. She came to our emergency room again where
her HR was 180 bpm and BP was 76/42 mmHg. EKG
showed SVT. Oral sotalol 80 mg was given. Electrical
cardioversion (synchronized 20 J) restored normal sinus
rhythm. A fetal monitor revealed a reassuring fetal heart-
beat. After observation for 6 hours in the emergency
department, with no more SVT attacks, she was dis-
charged. No further episodes of SVT occurred under
sotalol treatment. Owing to worries that SVT induced
by labor pains might cause maternal hemodynamic
compromise and fetal distress, a scheduled cesarean
section was performed smoothly at 38 weeks’ gesta-
tion. A male baby weighing 3,006 g was delivered with
Apgar scores of 9 at 1 minute and 9 at 5 minutes. The
mother’s postpartum course was uneventful, and she
was scheduled to receive further management in the
cardiologic outpatient department.
Discussion
Arrhythmias can occur de novo or can be exacerbated by
pregnancy. Potential risk factors in pregnancy that can
promote arrhythmogenesis include the hyperdynamic
state, the altered hormonal milieu, and underlying heart
disease [1]. Normal pregnancy is characterized by in-
creased cardiac output, reduced systemic vascular resist-
ance, and a modest decline in mean BP. These changes
are associated with a 10–15 bpm increase in HR. SVTs
include atrial tachycardia, atrioventricular nodal reen-
trant tachycardia (AVNRT), atrioventricular reentrant
tachycardia (AVRT), atrial flutter, and AF.
The most commonly encountered SVT in both
healthy gravid and nongravid patients is AVNRT, which
occurs in those with and without structural heart dis-
ease [2]. It is uncommon for AVNRT to cause any sig-
nificant problems for the healthy pregnant woman or
the fetus. In contrast, AVNRT occurring in the presence
of heart disease may produce hemodynamic instability
because of the rapidity of the tachycardia [3]. AVRT
caused by accessory pathways associated with some
forms of congenital heart disease is the second most
common form of SVT, and can result in serious hemo-
dynamic deterioration. AF is also rare in healthy preg-
nant women, but is encountered frequently in pregnant
women with underlying heart disease or thyrotoxico-
sis. It may have serious hemodynamic consequences in
patients with heart failure due to systolic or diastolic
dysfunction, congenital heart disease, or a rapidly con-
ducting antegrade accessory pathway [4].
Management of arrhythmias in pregnancy includes
the use of pharmacologic and non-pharmacologic ther-
apies, such as cardioversion and radiofrequency abla-
tion. All antiarrhythmic agents have the potential to
cause adverse effects in both the mother and the fetus.
Adenosine is indicated for the termination of acute
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AVNRT and AVRT, and its efficacy is >90%, without
obvious adverse effects. Adenosine is also recommended
for unknown types of SVT, because it can assist in their
differential diagnosis [5–8].
In our patient, the type of SVT was initially difficult to
determine. Adenosine was the first choice of treatment,
because AVNRT and AVRT are the most commonly en-
countered types of paroxysmal supraventricular tachy-
cardia. After challenged with adenosine, the HR declined
and a complete EKG showed AF with RVR. According to
American College of Cardiology/American Heart Asso-
ciation/European Society of Cardiology guidelines, the
class I recommendation for management of AF in preg-
nancy is to control the rate of ventricular response with
digoxin, a beta-blocker, or a calcium channel blocker.
Additionally, direct current cardioversion is indicated
if the patient is hemodynamically unstable because of
AF [9]. Verapamil (a calcium channel blocker) is effective
for AVNRT and AF or AF with RVR, with no reported
embryopathy or adverse fetal effects [10,11], but our
patient was refractory to verapamil and persistent SVT
with hemodynamic instability was noted. Digoxin was
not used in the emergency room on account of its narrow
therapeutic range and its ineffectiveness in controlling
ventricular rate during acute episodes. Amiodarone is
a highly effective drug for treating maternal and fetal
ventricular and SVTs, including those utilizing a bypass
tract, but it should be used cautiously in pregnancy
(class D). It is highly protein- and lipid-bound, resulting
in significant bodily storage, with a half-life of 26 days
to 6 months. Furthermore, each 200-mg tablet contains
75 mg of iodine, and serious adverse effects such as
neonatal hypothyroidism have been reported [12,13].
Our patient refused amiodarone. Electrical cardioversion
was, therefore, performed under sedation with propofol,
which was chosen for its rapid onset, short duration and
safety in pregnancy (class B). The HR returned to sinus
rhythm after synchronized DC shock. Electrical cardio-
version is well tolerated and effective in pregnant women
and should not be withheld if clinically indicated [7].
Because AF is rare in pregnancy unless associated
with underlying heart disease or thyrotoxicosis, cardiac
echo and thyroid function tests were performed in our
patient. Two-dimensional echocardiography revealed
moderate mitral regurgitation, moderate to severe tricus-
pid regurgitation, and dilated right and left atria. Dilated
atria caused by mitral and tricuspid regurgitation can
cause the myocardial fibers to stretch, so resulting in
abnormal electrical activity. Sotalol is a class III antiar-
rhythmic agent that blocks potassium channels, prolongs
action potential duration and lengthens QT intervals.
It is also a noncardiac selective beta-adrenergic blocker
and possesses 30% of the beta-blocking activity of 
propranolol. Sotalol demonstrates both antiarrhythmic
and rate controlling effects. Because the patient was
suffering from acute paroxysmal AF which could be re-
stored to normal sinus rhythm, anti-thrombotic therapy
was not required to prevent embolic events.
Taking into account the stress of labor pains, hemo-
dynamic changes after delivery and uncertainty during
the course of labor, a cesarean section was performed
smoothly at 38 weeks’ gestation. This was a successful
experience in managing a pregnant women with fre-
quent paroxysmal supraventricular tachycardia. External
cardioversion is safe and recommended if first-line
pharmacologic treatment fails and the patient remains
hemodynamically unstable.
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